Short Interest in Valneva SE (NASDAQ:VALN) Rises By 44.0%

Valneva SE (NASDAQ:VALN) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 22,900 shares, a growth of 44.0% from the December 31st total of 15,900 shares. Based on an average daily trading volume, of 41,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are short sold.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Valneva in a research note on Friday.

Valneva Trading Up 12.1 %

Shares of NASDAQ:VALN opened at $5.69 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The firm has a market capitalization of $461.96 million, a price-to-earnings ratio of -43.73 and a beta of 1.93. The business’s 50 day moving average price is $4.32 and its 200-day moving average price is $5.72.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.